Quantcast

Latest Bristol-Myers Squibb Stories

FDA Approves Novel AstraZeneca, Bristol-Meyers Squibb Diabetes Drug
2014-01-10 11:37:58

Ranjini Raghunath for redOrbit.com - Your Universe Online The FDA has approved the use of a new Type 2 diabetes drug called Farxiga, developed by pharmaceutical companies Bristol-Meyers Squibb and AstraZeneca. Type 2 diabetes affects 24 million people in the US and nearly 350 million people worldwide. Conventional diabetes drugs work by reducing the amount of sugar the body absorbs from food or by boosting the production of insulin which disposes of excess sugar. Farxiga, however,...

2014-01-09 08:26:49

Pharma Industry Veteran Brings Full-Spectrum Healthcare Expertise to One of Venture Industry's Most Active Life Sciences Investors CHEVY CHASE, Md. and MENLO PARK, Calif., Jan. 9, 2014 /PRNewswire/ -- New Enterprise Associates, Inc. (NEA), a leading global venture capital firm, today announced the appointment of Elliott Sigal, M.D., Ph.D. as Venture Partner and Senior Advisor. Dr. Sigal is a former Executive Vice President and Director for Bristol-Myers Squibb. He served as the...

2014-01-09 08:23:54

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, January 9, 2014 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Bristol-Myers Squibb Company (NYSE: BMY), Teva Pharmaceutical Industries Limited (NYSE: TEVA), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), AmerisourceBergen Corporation (NYSE: ABC), and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA). Today's readers may access these reports free of charge -...

2014-01-09 00:21:30

- First approved combination of oral targeted therapies for unresectable or metastatic melanoma with BRAF V600E or V600K mutations[1] LONDON, Jan. 8, 2014 /PRNewswire/ -- GlaxoSmithKline plc [LSE/NYSE: GSK ] announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist(® )(trametinib) for use in combination with Tafinlar(®) (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma...

2013-12-30 08:26:41

LONDON, Dec. 30, 2013 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Colorectal Cancer -- KOL Insight Module IntroductionThe global market for colorectal cancer (CRC) drugs is undergoing a fundamental shift due to wider generic competition in cytotoxics and increasing adoption of anti-EGFR products as first line therapies. What will be the impact on market leader Roche/Genetech's Avastin and how do leading clinicians view the changes? The main drivers...

2013-12-18 09:46:31

The epidermal growth factor receptor (EGFR) is expressed in normal colonic cells and is activated by specific peptide growth factors that regulate cell proliferation, survival and differentiation. Increased expression and activation of the EGFR has been observed in the majority of colorectal carcinoma (CRC), suggesting that the EGFR pathway plays an important role in colon carcinogenesis. The monoclonal antibodies cetuximab and panitumumab are capable of blocking EGFR activity and have...

2013-12-12 23:28:53

Rapid CYP2C19 Testing for Heart Attack Patients Using Antiplatelet Drugs in 150-Patient Clinical Trial With Spartan Bioscience Ottawa, Ontario (PRWEB) December 12, 2013 Spartan Bioscience today announced the start of a 150-patient study of personalized medicine for cardiac stent patients in Poland, Hungary, and Lithuania. The study is sponsored by the Medical University of Warsaw, and is entitled “Bedside Genetic or Pharmacodynamic Testing to Prevent Periprocedural Myonecrosis During...

2013-12-12 23:00:14

ResearchMoz.us include new market research report "Monoclonal Antibodies Market in Colorectal Cancer to 2019" to its huge collection of research reports. Click here to download detail report at http://www.researchmoz.us/monoclonal-antibodies-market-in-colorectal-cancer-to-2019-favorable-pricing-policy-in-the-us-and-rising-prevalence-in-europe-and-japan-ensures-market-growth-report.html. Albany, New York (PRWEB) December 13, 2013 GBI Research, has released the pharma report -...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.